Kadimastem (Israel) Performance
| KDST Stock | ILA 1,189 14.00 1.19% |
Kadimastem holds a performance score of 13 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 0.24, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Kadimastem's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kadimastem is expected to be smaller as well. Use Kadimastem coefficient of variation, jensen alpha, and the relationship between the downside deviation and standard deviation , to analyze future returns on Kadimastem.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Kadimastem are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Kadimastem sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 5.4 M | |
| Total Cashflows From Investing Activities | -380 K |
Kadimastem |
Kadimastem Relative Risk vs. Return Landscape
If you would invest 68,000 in Kadimastem on September 23, 2024 and sell it today you would earn a total of 50,900 from holding Kadimastem or generate 74.85% return on investment over 90 days. Kadimastem is generating 1.5608% of daily returns and assumes 8.9753% volatility on return distribution over the 90 days horizon. Simply put, 79% of stocks are less volatile than Kadimastem, and 69% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Kadimastem Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kadimastem's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Kadimastem, and traders can use it to determine the average amount a Kadimastem's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1739
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | KDST | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.98 actual daily | 79 79% of assets are less volatile |
Expected Return
| 1.56 actual daily | 31 69% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average Kadimastem is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kadimastem by adding it to a well-diversified portfolio.
Kadimastem Fundamentals Growth
Kadimastem Stock prices reflect investors' perceptions of the future prospects and financial health of Kadimastem, and Kadimastem fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Kadimastem Stock performance.
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 38.77 M | |||
| Shares Outstanding | 35.76 M | |||
| Price To Earning | (167.60) X | |||
| Price To Book | 5.90 X | |||
| EBITDA | (24.48 M) | |||
| Cash And Equivalents | 5.43 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 12.96 M | |||
| Debt To Equity | 7.80 % | |||
| Book Value Per Share | 0.23 X | |||
| Cash Flow From Operations | (21.55 M) | |||
| Earnings Per Share | (1.11) X | |||
| Total Asset | 27.34 M | |||
| Retained Earnings | (88 M) | |||
| Current Asset | 5 M | |||
| Current Liabilities | 11 M | |||
About Kadimastem Performance
By analyzing Kadimastem's fundamental ratios, stakeholders can gain valuable insights into Kadimastem's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Kadimastem has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Kadimastem has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. The company was founded in 2008 and is based in Ness Ziona, Israel. KADIMASTEM operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 28 people.Things to note about Kadimastem performance evaluation
Checking the ongoing alerts about Kadimastem for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Kadimastem help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Kadimastem is way too risky over 90 days horizon | |
| Kadimastem appears to be risky and price may revert if volatility continues | |
| Kadimastem has accumulated 12.96 M in total debt with debt to equity ratio (D/E) of 7.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Kadimastem has a current ratio of 0.38, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Kadimastem until it has trouble settling it off, either with new capital or with free cash flow. So, Kadimastem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kadimastem sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kadimastem to invest in growth at high rates of return. When we think about Kadimastem's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (26.27 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Kadimastem has accumulated about 5.43 M in cash with (21.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28. | |
| Roughly 54.0% of Kadimastem outstanding shares are owned by corporate insiders |
- Analyzing Kadimastem's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Kadimastem's stock is overvalued or undervalued compared to its peers.
- Examining Kadimastem's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Kadimastem's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Kadimastem's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Kadimastem's stock. These opinions can provide insight into Kadimastem's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Kadimastem Stock analysis
When running Kadimastem's price analysis, check to measure Kadimastem's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kadimastem is operating at the current time. Most of Kadimastem's value examination focuses on studying past and present price action to predict the probability of Kadimastem's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kadimastem's price. Additionally, you may evaluate how the addition of Kadimastem to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |